Richard A. Slayden - Publications

Affiliations: 
Cell and Molecular Biology (Graduate Degree Program) Colorado State University, Fort Collins, CO 
Area:
Microbiology Biology, Pathology, Molecular Biology

67 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Thanna S, Knudson SE, Grzegorzewicz A, Kapil S, Goins CM, Ronning DR, Jackson M, Slayden RA, Sucheck SJ. Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis. Organic & Biomolecular Chemistry. PMID 27251120 DOI: 10.1039/c6ob00821f  0.4
2016 Bommineni GR, Kapilashrami K, Cummings JE, Lu Y, Knudson SE, Gu C, Walker SG, Slayden RA, Tonge PJ. Thiolactomycin-based inhibitors of bacterial β-ketoacyl-ACP synthases with in vivo activity. Journal of Medicinal Chemistry. PMID 27187871 DOI: 10.1021/acs.jmedchem.6b00236  0.4
2016 Hemphill DD, McIlwraith CW, Slayden RA, Samulski RJ, Goodrich LR. Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis Osteoarthritis and Cartilage. 24: 902-911. DOI: 10.1016/j.joca.2015.12.001  0.4
2015 Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA. Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. The Journal of Antimicrobial Chemotherapy. PMID 26245639 DOI: 10.1093/jac/dkv226  0.4
2015 Crew R, Ramirez MV, England K, Slayden RA. MadR1, a Mycobacterium tuberculosis cell cycle stress response protein that is a member of a widely conserved protein class of prokaryotic, eukaryotic and archeal origin. Tuberculosis (Edinburgh, Scotland). 95: 251-8. PMID 25829286 DOI: 10.1016/j.tube.2015.03.005  0.4
2014 Knudson SE, Kumar K, Awasthi D, Ojima I, Slayden RA. In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 94: 271-6. PMID 24746463 DOI: 10.1016/j.tube.2014.03.007  0.4
2014 Schiebel J, Chang A, Shah S, Lu Y, Liu L, Pan P, Hirschbeck MW, Tareilus M, Eltschkner S, Yu W, Cummings JE, Knudson SE, Bommineni GR, Walker SG, Slayden RA, et al. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. The Journal of Biological Chemistry. 289: 15987-6005. PMID 24739388 DOI: 10.1074/jbc.M113.532804  0.4
2014 Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. Plos One. 9: e93953. PMID 24736743 DOI: 10.1371/journal.pone.0093953  0.4
2014 Park B, Awasthi D, Chowdhury SR, Melief EH, Kumar K, Knudson SE, Slayden RA, Ojima I. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents. Bioorganic & Medicinal Chemistry. 22: 2602-12. PMID 24726304 DOI: 10.1016/j.bmc.2014.03.035  0.4
2014 Pan P, Knudson SE, Bommineni GR, Li HJ, Lai CT, Liu N, Garcia-Diaz M, Simmerling C, Patil SS, Slayden RA, Tonge PJ. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy. Chemmedchem. 9: 776-91. PMID 24616444 DOI: 10.1002/cmdc.201300429  0.36
2014 Cummings JE, Beaupre AJ, Knudson SE, Liu N, Yu W, Neckles C, Wang H, Khanna A, Bommineni GR, Trunck LA, Schweizer HP, Tonge PJ, Slayden RA. Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy. 58: 1646-51. PMID 24379198 DOI: 10.1128/AAC.02296-13  0.4
2014 Cummings JE, Kingry LC, Rholl DA, Schweizer HP, Tonge PJ, Slayden RA. The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy. Antimicrobial Agents and Chemotherapy. 58: 931-5. PMID 24277048 DOI: 10.1128/AAC.00176-13  0.4
2013 O'Hara S, Wang K, Slayden RA, Schenkel AR, Huber G, O'Hern CS, Shattuck MD, Kirby M. Iterative feature removal yields highly discriminative pathways. Bmc Genomics. 14: 832. PMID 24274115 DOI: 10.1186/1471-2164-14-832  0.4
2013 Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I. SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents. Journal of Medicinal Chemistry. 56: 9756-70. PMID 24266862 DOI: 10.1021/jm401468w  0.4
2013 Ramirez MV, Dawson CC, Crew R, England K, Slayden RA. MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein. Bmc Microbiology. 13: 240. PMID 24172039 DOI: 10.1186/1471-2180-13-240  0.4
2013 Kumar K, Awasthi D, Lee SY, Cummings JE, Knudson SE, Slayden RA, Ojima I. Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorganic & Medicinal Chemistry. 21: 3318-26. PMID 23623254 DOI: 10.1016/j.bmc.2013.02.059  0.4
2013 Schenkel AR, Kingry LC, Slayden RA. The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection. Frontiers in Immunology. 4: 90. PMID 23596445 DOI: 10.3389/fimmu.2013.00090  0.4
2013 Slayden RA, Jackson M, Zucker J, Ramirez MV, Dawson CC, Crew R, Sampson NS, Thomas ST, Jamshidi N, Sisk P, Caspi R, Crick DC, McNeil MR, Pavelka MS, Niederweis M, et al. Updating and curating metabolic pathways of TB. Tuberculosis (Edinburgh, Scotland). 93: 47-59. PMID 23375378 DOI: 10.1016/j.tube.2012.11.001  0.4
2013 Kingry LC, Cummings JE, Brookman KW, Bommineni GR, Tonge PJ, Slayden RA. The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection. Journal of Bacteriology. 195: 351-8. PMID 23144254 DOI: 10.1128/JB.01957-12  0.4
2012 Yan R, Scott Lynn N, Kingry LC, Yi Z, Erickson T, Slayden RA, Dandy DS, Lear KL. Detection of virus-like nanoparticles via scattering using a chip-scale optical biosensor Applied Physics Letters. 101. DOI: 10.1063/1.4758294  0.4
2011 Li X, Liu N, Zhang H, Knudson SE, Li HJ, Lai CT, Simmerling C, Slayden RA, Tonge PJ. CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway. Acs Medicinal Chemistry Letters. 2: 818-823. PMID 22267981 DOI: 10.1021/ml200141e  0.4
2011 England K, Crew R, Slayden RA. Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress response. Bmc Microbiology. 11: 79. PMID 21504606 DOI: 10.1186/1471-2180-11-79  0.4
2011 Liu N, Cummings JE, England K, Slayden RA, Tonge PJ. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. The Journal of Antimicrobial Chemotherapy. 66: 564-73. PMID 21393229 DOI: 10.1093/jac/dkq509  0.4
2011 Thomas CJ, Casquilho-Gray HE, York J, DeCamp DL, Dai D, Petrilli EB, Boger DL, Slayden RA, Amberg SM, Sprang SR, Nunberg JH. A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus. The Journal of Biological Chemistry. 286: 6192-200. PMID 21159779 DOI: 10.1074/jbc.M110.196428  0.4
2011 Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. Journal of Medicinal Chemistry. 54: 374-81. PMID 21126020 DOI: 10.1021/jm1012006  0.4
2011 Kingry LC, Troyer RM, Marlenee NL, Bielefeldt-Ohmann H, Bowen RA, Schenkel AR, Dow SW, Slayden RA. Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes and Infection / Institut Pasteur. 13: 261-75. PMID 21070859 DOI: 10.1016/j.micinf.2010.10.022  0.4
2011 Yan R, Lynn NS, Kingry LC, Yi Z, Slayden RA, Dandy DS, Lear KL. Waveguide biosensor with integrated detector array for tuberculosis testing Applied Physics Letters. 98. DOI: 10.1063/1.3520142  0.4
2010 Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I. Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Medicinal Chemistry. 2: 1305-23. PMID 21339840 DOI: 10.4155/fmc.10.220  0.4
2010 Li X, Liu N, Zhang H, Knudson SE, Slayden RA, Tonge PJ. Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters. 20: 6306-9. PMID 20850304 DOI: 10.1016/j.bmcl.2010.08.076  0.4
2010 Yan R, Lynn NS, Kingry LC, Slayden RA, Dandy DS, Lear KL. An optical waveguide array biosensor for serology - biomed 2010. Biomedical Sciences Instrumentation. 46: 45-50. PMID 20467070  0.4
2010 Yan R, Kingry LC, Slayden RA, Lear KL. Immunoassay demonstration using a local evanescent array coupled biosensor Progress in Biomedical Optics and Imaging - Proceedings of Spie. 7559. DOI: 10.1117/12.842201  0.4
2010 Yan R, Lynn NS, Kingry LC, Slayden RA, Dandy DS, Leara KL. Demonstration of nanoparticle detection using a local evanescent array coupled biosensor 2010 23rd Annual Meeting of the Ieee Photonics Society, Photinics 2010. 214-215. DOI: 10.1109/PHOTONICS.2010.5698835  0.4
2010 Yan R, Scott Lynn N, Kingry LC, Dandy DS, Slayden RA, Lear KL. Waveguide biosensor with integrated photodetector array for tuberculosis serology Lasers and Electro-Optics/Quantum Electronics and Laser Science Conference: 2010 Laser Science to Photonic Applications, Cleo/Qels 2010 0.4
2010 Yan R, Scott Lynn N, Kingry LC, Dandy DS, Slayden RA, Lear KL. Waveguide biosensor with integrated photodetector array for tuberculosis serology Lasers and Electro-Optics/Quantum Electronics and Laser Science Conference: 2010 Laser Science to Photonic Applications, Cleo/Qels 2010 0.4
2009 England K, am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. The Journal of Antimicrobial Chemotherapy. 64: 1052-61. PMID 19734171 DOI: 10.1093/jac/dkp307  0.4
2009 Williams DL, Slayden RA, Amin A, Martinez AN, Pittman TL, Mira A, Mitra A, Nagaraja V, Morrison NE, Moraes M, Gillis TP. Implications of high level pseudogene transcription in Mycobacterium leprae. Bmc Genomics. 10: 397. PMID 19706172 DOI: 10.1186/1471-2164-10-397  0.4
2009 Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE. Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity. Bioorganic & Medicinal Chemistry. 17: 3588-94. PMID 19386501 DOI: 10.1016/j.bmc.2009.04.005  0.4
2009 Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, Kurosu M, Crick DC. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Molecular Microbiology. 72: 85-97. PMID 19220750 DOI: 10.1111/j.1365-2958.2009.06625.x  0.4
2009 Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. Acs Chemical Biology. 4: 221-31. PMID 19206187 DOI: 10.1021/cb800306y  0.4
2009 Slayden RA, Belisle JT. Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis. The Journal of Antimicrobial Chemotherapy. 63: 451-7. PMID 19109339 DOI: 10.1093/jac/dkn507  0.4
2009 Gonzalez-Juarrero M, Kingry LC, Ordway DJ, Henao-Tamayo M, Harton M, Basaraba RJ, Hanneman WH, Orme IM, Slayden RA. Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease. American Journal of Respiratory Cell and Molecular Biology. 40: 398-409. PMID 18787176 DOI: 10.1165/rcmb.2008-0248OC  0.4
2008 Respicio L, Nair PA, Huang Q, Anil B, Tracz S, Truglio JJ, Kisker C, Raleigh DP, Ojima I, Knudson DL, Tonge PJ, Slayden RA. Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery. Tuberculosis (Edinburgh, Scotland). 88: 420-9. PMID 18479968 DOI: 10.1016/j.tube.2008.03.001  0.4
2008 am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL, Johnson F, Peloquin CA, Slayden RA, Tonge PJ. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorganic & Medicinal Chemistry Letters. 18: 3029-33. PMID 18457948 DOI: 10.1016/j.bmcl.2008.04.038  0.4
2007 Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrobial Agents and Chemotherapy. 51: 3562-7. PMID 17664324 DOI: 10.1128/AAC.00383-07  0.4
2007 Huang Q, Tonge PJ, Slayden RA, Kirikae T, Ojima I. FtsZ: a novel target for tuberculosis drug discovery. Current Topics in Medicinal Chemistry. 7: 527-43. PMID 17346197 DOI: 10.2174/156802607780059790  0.4
2007 Tonge PJ, Kisker C, Slayden RA. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Current Topics in Medicinal Chemistry. 7: 489-98. PMID 17346194 DOI: 10.2174/156802607780059781  0.4
2006 Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. Acs Chemical Biology. 1: 43-53. PMID 17163639 DOI: 10.1021/cb0500042  0.4
2006 Groathouse NA, Amin A, Marques MA, Spencer JS, Gelber R, Knudson DL, Belisle JT, Brennan PJ, Slayden RA. Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles. Infection and Immunity. 74: 6458-66. PMID 16966411 DOI: 10.1128/IAI.00041-06  0.4
2006 Sartain MJ, Slayden RA, Singh KK, Laal S, Belisle JT. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Molecular & Cellular Proteomics : McP. 5: 2102-13. PMID 16899542 DOI: 10.1074/mcp.M600089-MCP200  0.4
2006 Slayden RA, Knudson DL, Belisle JT. Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. Microbiology (Reading, England). 152: 1789-97. PMID 16735741 DOI: 10.1099/mic.0.28762-0  0.4
2006 Groathouse NA, Brown SE, Knudson DL, Brennan PJ, Slayden RA. Isothermal amplification and molecular typing of the obligate intracellular pathogen Mycobacterium leprae isolated from tissues of unknown origins. Journal of Clinical Microbiology. 44: 1502-8. PMID 16597883 DOI: 10.1128/JCM.44.4.1502-1508.2006  0.4
2006 Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ, Ojima I. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. Journal of Medicinal Chemistry. 49: 463-6. PMID 16420032 DOI: 10.1021/jm050920y  0.4
2003 Phetsuksiri B, Jackson M, Scherman H, McNeil M, Besra GS, Baulard AR, Slayden RA, DeBarber AE, Barry CE, Baird MS, Crick DC, Brennan PJ. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. The Journal of Biological Chemistry. 278: 53123-30. PMID 14559907 DOI: 10.1074/jbc.M311209200  0.4
2003 Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. Journal of Combinatorial Chemistry. 5: 172-87. PMID 12625709 DOI: 10.1021/cc020071p  0.4
2002 Slayden RA, Barry CE. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis Tuberculosis. 82: 149-160. PMID 12464486 DOI: 10.1054/tube.2002.0333  0.4
2002 Rosenkrands I, Slayden RA, Crawford J, Aagaard C, Barry CE, Andersen P. Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. Journal of Bacteriology. 184: 3485-91. PMID 12057942 DOI: 10.1128/JB.184.13.3485-3491.2002  0.4
2000 Slayden RA, Lee RE, Barry CE. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis Molecular Microbiology. 38: 514-525. PMID 11069675 DOI: 10.1046/j.1365-2958.2000.02145.x  0.4
2000 Slayden RA, Barry CE. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis Microbes and Infection. 2: 659-669. PMID 10884617 DOI: 10.1016/S1286-4579(00)00359-2  0.4
2000 Behr MA, Schroeder BG, Brinkman JN, Slayden RA, Barry CE. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. Journal of Bacteriology. 182: 3394-9. PMID 10852869 DOI: 10.1128/JB.182.12.3394-3399.2000  0.4
2000 Wang L, Slayden RA, Barry CE, Liu J. Cell wall structure of a mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids Journal of Biological Chemistry. 275: 7224-7229. PMID 10702292 DOI: 10.1074/jbc.275.10.7224  0.4
2000 Barry CE, Slayden RA, Sampson AE, Lee RE. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs Biochemical Pharmacology. 59: 221-231. PMID 10609550 DOI: 10.1016/S0006-2952(99)00253-1  0.4
1998 Barry CE, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA, Yuan Y. Mycolic acids: structure, biosynthesis and physiological functions. Progress in Lipid Research. 37: 143-79. PMID 9829124 DOI: 10.1016/S0163-7827(98)00008-3  0.4
1998 Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science (New York, N.Y.). 280: 1607-10. PMID 9616124 DOI: 10.1126/science.280.5369.1607  0.4
1998 Barry CE, Slayden RA, Mdluli K. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis Drug Resistance Updates. 1: 128-134. DOI: 10.1016/S1368-7646(98)80028-9  0.4
1996 Slayden RA, Lee RE, Armour JW, Cooper AM, Orme IM, Brennan PJ, Besra GS. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis Antimicrobial Agents and Chemotherapy. 40: 2813-2819. PMID 9124847  0.4
1995 Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol Antimicrobial Agents and Chemotherapy. 39: 2484-2489. PMID 8585730  0.4
1994 Besra GS, Sievert T, Lee RE, Slayden RA, Brennan PJ, Takayama K. Identification of the apparent carrier in mycolic acid synthesis Proceedings of the National Academy of Sciences of the United States of America. 91: 12735-12739. PMID 7809112 DOI: 10.1073/pnas.91.26.12735  0.4
Show low-probability matches.